Lexaria Bioscience Corp. (LEXX)

PriceLoading quote

Financial charts

Revenue

Net income

Free cash flow

Total cash / debt

CashTotal debt

Financial statements

16 annual periodsNewest to oldest
2025202420232022202120202019201820172016201520142013201220112010
Revenue$705,923$464,278$226,208$255,397$722,738$384,543$222,610$433,287$63,639$40,718
Gross profit$703,203$459,456$194,708$183,556$547,392$215,415$199,717$408,102$33,889−$4,897−$15,181$0$302,251$574,494$465,911$88,856
Research & development$8.2M$2.4M$3.7M$1.8M$1.3M$387,074$555,730$492,864$54,185$9,024$146,466$0
Operating expenses$12.6M$6.2M$6.7M$6.8M$6.2M$4.4M$4.4M$7.0M$2.0M$1.3M$2.0M$1.6M$645,802$826,002$1.0M$641,318
Operating income−$11.9M−$5.8M−$6.5M−$6.6M−$5.7M−$1.3M−$2.0M−$1.6M
EBITDAderived−$11.8M−$5.7M−$6.4M−$6.5M−$5.6M
Net income−$11.9M−$5.8M−$6.7M−$7.3M−$4.0M−$4.1M−$4.2M−$6.6M−$1.9M−$1.3M−$2.0M−$1.6M−$538,226−$552,462
Basic EPSper diluted share-$0.95-$1.47-$0.05-$0.09-$0.03-$0.03-$0.04-$0.14-$0.02-$0.02-$0.04
Diluted EPSper diluted share-$0.66-$0.47-$1.01-$0.95-$1.47-$0.05-$0.09-$0.03-$0.03-$0.04-$0.14-$0.02-$0.02-$0.04-$0.04

Insider buys & sells

Jul 1, 2024Jun 30, 2026
Buys9$172.3K disclosed value
Sells (SEC code S)1$10.3K disclosed value
10 recent transactions
TransactionInsiderTypeSharesPriceValueOwned after
Jul 30, 2025Form 4BUNKA CHRISTOPHERDirectorBuycommon shares · indirect11.9K$0.91$10.8K281.9K
Jul 29, 2025Form 4BUNKA CHRISTOPHERDirectorBuycommon shares · indirect15.6K$0.92$14.4K270.0K
Jul 29, 2025Form 4McKechnie William EdwardDirectorBuycommon shares5.0K$0.91$4.5K18.2K
Jul 29, 2025Form 4DOCHERTY JOHN MARTINPresident & CSOBuycommon shares5.4K$0.93$5.0K5.4K
Jul 29, 2025Form 4Carle VanessaSecretaryBuycommon shares750$0.91$682.50750